Summary
Arvinas Inc (Arvinas) is a biopharmaceutical company that develops therapeutics. The company develops novel therapeutics for the treatment of various diseases such as pro-inflammatory, cancer, autoimmune and rare diseases. Its proprietary approach is to target disease causing proteins, degrade them and remove them from the body. Arvinas’s protein degradation technology platforms include proteolysis-targeting chimera and hydrophobic tagging that induce the loss of intracellular proteins. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations. It also develops degraders for targets in cancer, including androgen receptor, estrogen receptor and BET proteins. Arnivas is headquartered in New Haven, Connecticut, the US.
Arvinas Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arvinas Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Arvinas Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Arvinas Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Arvinas Raises USD41.6 Million in Series B Venture Financing 10
Arvinas Raises US$18.25 Million In Series A Venture Financing 11
Arvinas Raises USD3.51 Million in Venture Financing 12
Licensing Agreements 13
Genentech Enters into Licensing Agreement with Arvinas 13
Arvinas Enters into Licensing Agreement with Merck 14
Arvinas Inc - Key Competitors 15
Key Employees 16
Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18
List of Tables
Arvinas Inc, Pharmaceuticals & Healthcare, Key Facts 1
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arvinas Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arvinas Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Arvinas Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Arvinas Raises USD41.6 Million in Series B Venture Financing 10
Arvinas Raises US$18.25 Million In Series A Venture Financing 11
Arvinas Raises USD3.51 Million in Venture Financing 12
Genentech Enters into Licensing Agreement with Arvinas 13
Arvinas Enters into Licensing Agreement with Merck 14
Arvinas Inc, Key Competitors 15
Arvinas Inc, Key Employees 16
List of Figures
Arvinas Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arvinas Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8